Literature DB >> 34078315

Promoting HIV indicator condition-guided testing in hospital settings (PROTEST 2.0): study protocol for a multicentre interventional study.

Saskia J Bogers1, Maarten F Schim van der Loeff2,3, Udi Davidovich3, Anders Boyd3,4, Marc van der Valk2, Kees Brinkman5, Godelieve J de Bree2, Peter Reiss2,4,6,7, Jan E A M van Bergen8,9, Suzanne E Geerlings2.   

Abstract

BACKGROUND: Late presentation remains a key barrier towards controlling the HIV epidemic. Indicator conditions (ICs) are those that are AIDS-defining, associated with a prevalence of undiagnosed HIV > 0.1%, or whose clinical management would be impeded if an HIV infection were undiagnosed. IC-guided HIV testing is an effective strategy in identifying undiagnosed HIV, but opportunities for earlier HIV diagnosis through IC-guided testing are being missed. We present a protocol for an interventional study to improve awareness of IC-guided testing and increase HIV testing in patients presenting with ICs in a hospital setting.
METHODS: We designed a multicentre interventional study to be implemented at five hospitals in the region of Amsterdam, the Netherlands. Seven ICs were selected for which HIV test ratios (proportion of patients with an IC tested for HIV) will be measured: tuberculosis, cervical/vulvar cancer or high-grade cervical/vulvar dysplasia, malignant lymphoma, hepatitis B and C, and peripheral neuropathy. Prior to the intervention, a baseline assessment of HIV test ratios across ICs will be performed in eligible patients (IC diagnosed January 2015 through May 2020, ≥18 years, not known HIV positive) and an assessment of barriers and facilitators for HIV testing amongst relevant specialties will be conducted using qualitative (interviews) and quantitative methods (questionnaires). The intervention phase will consist of an educational intervention, including presentation of baseline results as competitive graphical audit and feedback combined with discussion on implementation and opportunities for improvement. The effect of the intervention will be assessed by comparing HIV test ratios of the pre-intervention and post-intervention periods. The primary endpoint is the HIV test ratio within ±3 months of IC diagnosis. Secondary endpoints are the HIV test ratio within ±6 months of diagnosis, ratio ever tested for HIV, HIV positivity percentage, proportion of late presenters and proportion with known HIV status prior to initiating treatment for their IC. DISCUSSION: This protocol presents a strategy aimed at increasing awareness of the benefits of IC-guided testing and increasing HIV testing in patients presenting with ICs in hospital settings to identify undiagnosed HIV in Amsterdam, the Netherlands. TRIAL REGISTRATION: Dutch trial registry: NL7521 . Registered 14 February 2019.

Entities:  

Keywords:  HIV testing; Healthcare quality improvement; Implementation; Indicator condition; Multifaceted intervention

Year:  2021        PMID: 34078315     DOI: 10.1186/s12879-021-06183-8

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


  26 in total

Review 1.  Cost-effectiveness of HIV screening in high-income countries: A systematic review.

Authors:  Fabrizio Bert; Maria Rosaria Gualano; Paolo Biancone; Valerio Brescia; Elisa Camussi; Maria Martorana; Silvana Secinaro; Roberta Siliquini
Journal:  Health Policy       Date:  2018-03-23       Impact factor: 2.980

2.  Prevention of HIV-1 infection with early antiretroviral therapy.

Authors:  Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming
Journal:  N Engl J Med       Date:  2011-07-18       Impact factor: 91.245

3.  Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy.

Authors:  Caroline A Sabin; Colette J Smith; Helen Gumley; Gabrielle Murphy; Fiona C Lampe; Andrew N Phillips; Beth Prinz; Mike Youle; Margaret A Johnson
Journal:  AIDS       Date:  2004-11-05       Impact factor: 4.177

4.  The high cost of medical care for patients who present late (CD4 <200 cells/microL) with HIV infection.

Authors:  H B Krentz; M C Auld; M J Gill
Journal:  HIV Med       Date:  2004-03       Impact factor: 3.180

5.  Routine HIV screening in France: clinical impact and cost-effectiveness.

Authors:  Yazdan Yazdanpanah; Caroline E Sloan; Cécile Charlois-Ou; Stéphane Le Vu; Caroline Semaille; Dominique Costagliola; Josiane Pillonel; Anne-Isabelle Poullié; Olivier Scemama; Sylvie Deuffic-Burban; Elena Losina; Rochelle P Walensky; Kenneth A Freedberg; A David Paltiel
Journal:  PLoS One       Date:  2010-10-01       Impact factor: 3.240

6.  The potential impact of routine testing of individuals with HIV indicator diseases in order to prevent late HIV diagnosis.

Authors:  Paola Scognamiglio; Giacomina Chiaradia; Gabriella De Carli; Massimo Giuliani; Claudio Maria Mastroianni; Stefano Aviani Barbacci; Anna Rita Buonomini; Susanna Grisetti; Alessandro Sampaolesi; Angela Corpolongo; Nicoletta Orchi; Vincenzo Puro; Giuseppe Ippolito; Enrico Girardi
Journal:  BMC Infect Dis       Date:  2013-10-10       Impact factor: 3.090

7.  Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study).

Authors:  Ann K Sullivan; Dorthe Raben; Joanne Reekie; Michael Rayment; Amanda Mocroft; Stefan Esser; Agathe Leon; Josip Begovac; Kees Brinkman; Robert Zangerle; Anna Grzeszczuk; Anna Vassilenko; Vesna Hadziosmanovic; Maksym Krasnov; Anders Sönnerborg; Nathan Clumeck; José Gatell; Brian Gazzard; Antonella d'Arminio Monforte; Jürgen Rockstroh; Jens D Lundgren
Journal:  PLoS One       Date:  2013-01-15       Impact factor: 3.240

8.  Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study.

Authors:  D Raben; A Mocroft; M Rayment; V M Mitsura; V Hadziosmanovic; Z M Sthoeger; A Palfreeman; S Morris; G Kutsyna; A Vassilenko; J Minton; C Necsoi; V P Estrada; A Grzeszczuk; V Svedhem Johansson; J Begovac; E L C Ong; A Cabié; F Ajana; B M Celesia; F Maltez; M Kitchen; L Comi; U B Dragsted; N Clumeck; J Gatell; B Gazzard; A d'Arminio Monforte; J Rockstroh; Y Yazdanpanah; K Champenois; M L Jakobsen; A Sullivan; J D Lundgren
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

9.  Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE).

Authors:  Amanda Mocroft; Jens D Lundgren; Miriam Lewis Sabin; Antonella d'Arminio Monforte; Norbert Brockmeyer; Jordi Casabona; Antonella Castagna; Dominique Costagliola; Francois Dabis; Stéphane De Wit; Gerd Fätkenheuer; Hansjakob Furrer; Anne M Johnson; Marios K Lazanas; Catherine Leport; Santiago Moreno; Niels Obel; Frank A Post; Joanne Reekie; Peter Reiss; Caroline Sabin; Adriane Skaletz-Rorowski; Ignacio Suarez-Lozano; Carlo Torti; Josiane Warszawski; Robert Zangerle; Céline Fabre-Colin; Jesper Kjaer; Genevieve Chene; Jesper Grarup; Ole Kirk
Journal:  PLoS Med       Date:  2013-09-03       Impact factor: 11.069

10.  Five-year risk of HIV diagnosis subsequent to 147 hospital-based indicator diseases: a Danish nationwide population-based cohort study.

Authors:  Lars Haukali Omland; Rebecca Legarth; Magnus Glindvad Ahlström; Henrik Toft Sørensen; Niels Obel
Journal:  Clin Epidemiol       Date:  2016-09-06       Impact factor: 4.790

View more
  1 in total

1.  Improving indicator-condition guided testing for HIV in the hospital setting (PROTEST 2·0): A multicenter, interrupted time-series analysis.

Authors:  Saskia J Bogers; Maarten F Schim van der Loeff; Anders Boyd; Udi Davidovich; Marc van der Valk; Kees Brinkman; Kim Sigaloff; Judith Branger; Nejma Bokhizzou; Godelieve J de Bree; Peter Reiss; Jan E A M van Bergen; Suzanne E Geerlings
Journal:  Lancet Reg Health Eur       Date:  2022-10-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.